Literature DB >> 24563239

Plasma triglyceride levels may modulate hepatitis C viral replication.

David H Van Thiel1, Magdalena George, Bashar M Attar, Giuliano Ramadori, Niculae Ion-Nedelcu.   

Abstract

BACKGROUND: Plasma and hepatic lipid abnormalities are frequent in hepatitis C infected individuals.
METHODS: Plasma lipid and medical records profiles were prospectively obtained in 130 consecutive individuals seen by a single hepatologist in a university liver disease clinic. The relationships between viral load, genotype, plasma lipid fractions, HDL, LDL particle number and particle size were examined.
RESULTS: Of 130 individuals studied, 74 had hepatitis C while 15 had NAFLD/NASH and 30 had alcohol related liver disease. The LDL particle number and LDL-C levels did not differ between those with and without hepatitis C although the number of small LDL particles was greater in those with hepatitis C infection. The HDL-C and total cholesterol levels were greater in those without hepatitis C than those with hepatitis C (P = 0.009). In contrast, the serum triglyceride level was greater in the hepatitis C viral group (P = 0.013). Importantly, the hepatitis C viral load regardless of the genotype correlated directly with the triglyceride and VLDL levels with r values of 0.73 and 0.84, respectively.
CONCLUSIONS: There are: (1) important differences in lipid classes, number and the size of lipid particles exist between hepatitis C virus infected and noninfected liver disease groups, (2) the serum total triglyceride and the LDL levels correlate significantly with the hepatitis C viral load and, (3) Serum triglyceride level may play an important role in viral replication. These data further suggest that therapies directed at lowering plasma triglyceride levels may enhance the efficacy of current antiviral treatment regimens.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24563239     DOI: 10.1007/s10620-014-3079-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  40 in total

1.  Statins improve ALT values in chronic hepatitis C patients with abnormal values.

Authors:  Mohammad F Madhoun; Ted Bader
Journal:  Dig Dis Sci       Date:  2010-03       Impact factor: 3.199

2.  Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation.

Authors:  Pierluigi Toniutto; Carlo Fabris; Claudio Avellini; Rosalba Minisini; Davide Bitetto; Elisabetta Rossi; Carlo Smirne; Mario Pirisi
Journal:  World J Gastroenterol       Date:  2005-10-14       Impact factor: 5.742

3.   Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma.

Authors:  Mahmoud A Khattab; Mohammed Eslam; Yousef I Mousa; Nosa Ela-adawy; Shimaa Fathy; Mohammed Shatat; Hesham Abd-Aalhalim; Amal Kamal; Mohammed A Sharawe
Journal:  Ann Hepatol       Date:  2012 Jul-Aug       Impact factor: 2.400

4.  High plasma level of nucleocapsid-free envelope glycoprotein-positive lipoproteins in hepatitis C patients.

Authors:  Caroline Scholtes; Christophe Ramière; Dominique Rainteau; Laure Perrin-Cocon; Claude Wolf; Lydie Humbert; Martine Carreras; Aurélie Guironnet-Paquet; Fabien Zoulim; Ralf Bartenschlager; Vincent Lotteau; Patrice André; Olivier Diaz
Journal:  Hepatology       Date:  2012-04-25       Impact factor: 17.425

5.  Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.

Authors:  Stephen A Harrison; Lorenzo Rossaro; Ke-Qin Hu; Keyur Patel; Hans Tillmann; Sandeep Dhaliwal; Dawn M Torres; Kenneth Koury; Venkata S Goteti; Stephanie Noviello; Clifford A Brass; Janice K Albrecht; John G McHutchison; Mark S Sulkowski
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

6.  Managing to low-density lipoprotein particles compared with low-density lipoprotein cholesterol: a cost-effectiveness analysis.

Authors:  John A Rizzo; Peter J Mallow; Heidi C Waters; Gregory S Pokrywka
Journal:  J Clin Lipidol       Date:  2013-06-18       Impact factor: 4.766

Review 7.  Lipids: a key for hepatitis C virus entry and a potential target for antiviral strategies.

Authors:  Julie Blaising; Eve-Isabelle Pécheur
Journal:  Biochimie       Date:  2012-08-01       Impact factor: 4.079

8.  Correlation of serum HCV core concentration with blood level of lipid and antioxidants in various forms of liver diseases.

Authors:  M Irshad; Indranil Dhar; Swati Gupta; Y K Joshi
Journal:  Hepatogastroenterology       Date:  2007 Apr-May

9.  Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection.

Authors:  Ching-Sheng Hsu; Chen-Hua Liu; Chun-Jen Liu; Chia-Chi Wang; Chi-Ling Chen; Ming-Yang Lai; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Am J Gastroenterol       Date:  2009-02-10       Impact factor: 10.864

10.  Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol.

Authors:  Alexander Monto; Judy Alonzo; Jessica J Watson; Carl Grunfeld; Teresa L Wright
Journal:  Hepatology       Date:  2002-09       Impact factor: 17.425

View more
  1 in total

1.  Association of Serum Lipids with Hepatic Steatosis, Stage of Liver Fibrosis and Viral Load in Chronic Hepatitis C.

Authors:  Ivan Valkov; Radina Ivanova; Assen Alexiev; Krasimir Antonov; Lyudmila Mateva
Journal:  J Clin Diagn Res       Date:  2017-08-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.